HTLV-1 Tax oncoprotein is considered a key factor in HTLV-1 pathogenicity. BRCA1 gene dysfunction can lead to breast cancer development. In contrast to the tumor suppressor nature of BRCA1, Tax is a potent oncoprotein, most of its activities are strictly opposing those of BRCA1. Therefore, we hypothesize that HTLV-1 Tax expression in breast epithelial cells can antagonize BRCA1 expression and functionality, thereby sensitizing these cells to malignant transformation by environmental carcinogens. So, the main objective of this study is to provide molecular and cellular indications to validate this hypothesis. Based on earlier findings that milk of HTLV-1 infected women is rich in HTLV-1 infected lymphocytes that can transfer the virus into breast epithelial cells, the outcomes of our present project may point that HTLV-1 can be a risk factor for the development of breast cancer, with a substantially higher risk to women who practice long-term breastfeeding. Our results showed that Tax strongly inhibited estrogen induced activation of BRCA-1 expression in breast cells by sequestering CBP/p300 co-activators. It seems that Tax does not prevent the binding of CBP/p300 to ERα but rather physically associates with the ERα-CBP/p300 to form a tertiaryreporter ERα-CBP/p300-Tax. Since CBP/p300 have several binding domains, we believe that Tax associates with ER1α-CBP/p300 complex through binding to CBP/p300 rather than to the ER1α protein. By CHIP assay, our results proved also that Tax was able to prevent the ERα complex binding to BRCA-1 promoter. We have also found that Tax inhibits BRCA1-mediated activation of p53-target promoters by inactivating p53.
